Who is sponsoring NCT00667199?

NCT00667199 is sponsored by Bayer.

What drugs are being tested in NCT00667199?

Interventions in NCT00667199: Radium-223 dichloride (BAY88-8223).

What condition does NCT00667199 study?

NCT00667199 studies Hormone Refractory Prostate Cancer, Bone Metastases.

Is NCT00667199 still recruiting?

NCT00667199 is currently completed. Last updated 19 April 2023.

Last reviewed 2023-04-19 · How we verify

NCT00667199

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BAY88-8223, Does Response Study in HRPC Patients

Completed Phase 2 Last updated 19 April 2023

What this trial tests

Phase 2 trial testing Radium-223 dichloride (BAY88-8223) in Hormone Refractory Prostate Cancer in 100 participants. Completed in 6 October 2009.

Timeline

30 May 2005

Primary endpoint
1 April 2008

6 October 2009

Quick facts

Lead sponsor	Bayer
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	100
Start date	30 May 2005
Primary completion	1 April 2008
Estimated completion	6 October 2009

Drugs / interventions tested

Radium-223 dichloride (BAY88-8223) — full drug profile →

Conditions studied

Hormone Refractory Prostate Cancer — all drugs for Hormone Refractory Prostate Cancer →
Bone Metastases — all drugs for Bone Metastases →

Sponsor

Bayer — full company profile →

Who can join

40 and older, male only, with Hormone Refractory Prostate Cancer or Bone Metastases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the efficacy and safety of the investigational radioisotope Radium-223, Xofigo (Alpharadin), in treatment of men with prostate cancer and bone metastases that no longer respond to hormonal treatment.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Evolving treatment approaches for the management of metastatic castration-resistant prostate cancer - role of radium-223.
Mukherji D, El Dika I, Temraz S, Haidar M, et al · · 2014 · cited 6× · PMID 24920911 · DOI 10.2147/tcrm.s45667
WITHDRAWN: Radioisotopes for metastatic bone pain.
Roqué I Figuls M, Martinez-Zapata MJ, Scott-Brown M, Alonso-Coello P. · · 2017 · cited 3× · PMID 28334435 · DOI 10.1002/14651858.cd003347.pub3

Verify or expand the search:

Other trials of Radium-223 dichloride (BAY88-8223)

Trials testing the same drug.

NCT01618370 — Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Meta · Phase 3 · completed
NCT01798108 — Dose Escalation Study of Radium-223 Dichloride in Patients With Advanced Skeletal Metastases · Phase 1 · completed

Other recruiting trials for Hormone Refractory Prostate Cancer

Currently open trials in the same condition.

NCT02955082 — The BARCODE 2 Study - The Use of Genetic Profiling to Guide Prostate Cancer Treatment · Phase 2 · active not recruiting

Other Bayer trials

Trials by the same sponsor.

NCT05900388 — A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolis · not yet recruiting
NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
NCT05477953 — An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About · not yet recruiting
NCT07192952 — A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Child · Phase 3 · not yet recruiting
NCT07450599 — A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Befo · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00667199 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bayer
Last refreshed: 19 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00667199.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing